[go: up one dir, main page]

MX2018006500A - Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos. - Google Patents

Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos.

Info

Publication number
MX2018006500A
MX2018006500A MX2018006500A MX2018006500A MX2018006500A MX 2018006500 A MX2018006500 A MX 2018006500A MX 2018006500 A MX2018006500 A MX 2018006500A MX 2018006500 A MX2018006500 A MX 2018006500A MX 2018006500 A MX2018006500 A MX 2018006500A
Authority
MX
Mexico
Prior art keywords
viruses
antigens
bank
damaged
vaccine against
Prior art date
Application number
MX2018006500A
Other languages
English (en)
Other versions
MX393033B (es
Inventor
Sonoda Kengo
Shinmura Yasuhiko
Yamaori Susumu
Abe Motoharu
Maruno Shinichi
Takagi Shota
Hayashi Yasuhisa
Kameyama Kazuhisa
Komura Fusae
Uchida Naomi
Yoshimura Masaya
Fukuda Aki
Original Assignee
The Chemo Sero Therapeutic Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo Sero Therapeutic Res Institute filed Critical The Chemo Sero Therapeutic Res Institute
Publication of MX2018006500A publication Critical patent/MX2018006500A/es
Publication of MX393033B publication Critical patent/MX393033B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se inventó una vacuna contra el dengue altamente segura que indujo una respuesta de anticuerpos neutralizantes contra los cuatro serotipos del virus del dengue sin desarrollar más que un nivel fijo de viremia con una sola administración; se proporciona una formulación de virus de dengue tetravalente que es excelente tanto en eficacia (respuesta de anticuerpos neutralizantes) como en seguridad (viremia).
MX2018006500A 2015-11-27 2016-11-25 Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antígenos. MX393033B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015232013 2015-11-27
PCT/JP2016/085077 WO2017090762A1 (ja) 2015-11-27 2016-11-25 デングウイルス弱毒株をバンク化した生ウイルス、及びそれらを抗原とするデングワクチン

Publications (2)

Publication Number Publication Date
MX2018006500A true MX2018006500A (es) 2019-02-26
MX393033B MX393033B (es) 2025-03-24

Family

ID=58763255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006500A MX393033B (es) 2015-11-27 2016-11-25 Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antígenos.

Country Status (17)

Country Link
US (1) US10655110B2 (es)
EP (1) EP3382012A4 (es)
JP (2) JP6910956B2 (es)
KR (2) KR102297300B1 (es)
CN (1) CN108699534B (es)
AU (1) AU2016360487C1 (es)
BR (1) BR112018010690A8 (es)
CA (1) CA3005814C (es)
IL (1) IL259451B (es)
MX (1) MX393033B (es)
MY (1) MY194650A (es)
NZ (1) NZ782252A (es)
PH (1) PH12018501107A1 (es)
SG (2) SG11201804317YA (es)
TW (1) TWI736563B (es)
WO (1) WO2017090762A1 (es)
ZA (1) ZA201803441B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116143914B (zh) * 2022-12-30 2023-08-22 珠海重链生物科技有限公司 一种针对登革病毒ns1蛋白的抗体及其相关应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
AU2001238441B2 (en) * 2000-02-16 2006-10-26 Mahidol University Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
MX2007015873A (es) 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.
KR20080018271A (ko) * 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
AR061197A1 (es) 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2012051461A2 (en) * 2010-10-13 2012-04-19 Primordial Soup, Llc Screw captivator
US20150196631A1 (en) * 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
SG10201702292YA (en) * 2012-09-21 2017-05-30 Agency Science Tech & Res Novel attenuated dengue virus strains for vaccine application
JP6818548B2 (ja) * 2013-03-15 2021-01-20 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法

Also Published As

Publication number Publication date
JPWO2017090762A1 (ja) 2018-09-20
CA3005814C (en) 2022-09-27
AU2016360487C1 (en) 2021-07-22
KR102373570B1 (ko) 2022-03-10
WO2017090762A1 (ja) 2017-06-01
NZ742683A (en) 2021-08-27
NZ778410A (en) 2025-07-25
IL259451A (en) 2018-07-31
NZ782252A (en) 2025-12-19
JP2021168672A (ja) 2021-10-28
CN108699534A (zh) 2018-10-23
ZA201803441B (en) 2025-10-29
IL259451B (en) 2022-01-01
US20180340155A1 (en) 2018-11-29
MY194650A (en) 2022-12-09
AU2016360487A2 (en) 2018-07-26
JP7232289B2 (ja) 2023-03-02
SG10201913338XA (en) 2020-02-27
KR20210083384A (ko) 2021-07-06
AU2016360487A1 (en) 2018-07-12
CA3005814A1 (en) 2017-06-01
AU2016360487B2 (en) 2021-01-21
BR112018010690A2 (pt) 2018-11-13
BR112018010690A8 (pt) 2019-02-26
US10655110B2 (en) 2020-05-19
KR102297300B1 (ko) 2021-09-02
TWI736563B (zh) 2021-08-21
JP6910956B2 (ja) 2021-07-28
TW201726913A (zh) 2017-08-01
EP3382012A1 (en) 2018-10-03
KR20180080331A (ko) 2018-07-11
MX393033B (es) 2025-03-24
PH12018501107A1 (en) 2019-01-21
EP3382012A4 (en) 2019-07-03
SG11201804317YA (en) 2018-06-28
CN108699534B (zh) 2022-05-24

Similar Documents

Publication Publication Date Title
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO2018003451A2 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
PH12015502230B1 (en) Novel viral replication inhibitors
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MX369039B (es) Vacuna contra el circovirus porcino tipo 2.
MX394998B (es) Virus de vacuna del sindrome respiratorio y reproductivo porcino.
MX2018006500A (es) Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos.
AR117942A1 (es) Vacunas contra el zika, composiciones inmunogénicas y métodos que las utilizan
EA201892348A1 (ru) Комбинации и способы, включающие ингибитор сборки капсида
EA201792083A1 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
MX2024007379A (es) Vacunas para el virus del papiloma humano y metodos para su uso.